Cliff Asness’s Lineage Cell Therapeutics LCTX Stock Holding History
Bought
Maintained
Sold
Other funds holding LCTX
Cliff Asness's LCTX Position: Q3 2026 in Review
Cliff Asness opened a new position in Lineage Cell Therapeutics (LCTX) in Q3 2026: 12,097 shares worth $11.6K. The stake represents ﹤0.01% of the portfolio and ranks #4046 among its holdings. This is a return to the name: Cliff Asness previously reported a position in LCTX as recently as Q3 2025.
Cliff Asness first reported a position in LCTX in Q2 2015 and has held it in 10 quarters since. The position peaked at $254K in Q3 2021. 140 funds tracked by Wall St. Rank hold LCTX as of Q3 2026.
- Cliff Asness held 12,097 shares of Lineage Cell Therapeutics worth $11.6K as of Q3 2026.
- Lineage Cell Therapeutics was a new Cliff Asness position in Q3 2026.
- Lineage Cell Therapeutics made up ﹤0.01% of Cliff Asness's portfolio in Q3 2026, its #4046 holding.
- Cliff Asness first reported a position in Lineage Cell Therapeutics in Q2 2015 and has held it in 10 quarters since.
- Cliff Asness's Lineage Cell Therapeutics position peaked at $254K in Q3 2021.
- 140 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q3 2026.
Based on AQR Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.